ClearPoint director settles 12,417 RSUs into shares

ClearPoint Neuro director Pascal E. R. Girin settled a restricted stock unit award into common shares.

Rhea-AI Filing Summary

ClearPoint Neuro director Pascal E. R. Girin settled a restricted stock unit award into common shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro, Inc. common stock at no cash exercise price. After this settlement, he directly holds 110,623 common shares. The RSUs were originally granted on May 22, 2025 and vested on their scheduled vesting date tied to the earlier of the first anniversary of grant or the day before the company’s 2026 annual meeting of stockholders.

Insider Trade Summary

12,417 shares exercised/converted

Exercise 2 txns

Insider Girin Pascal E R

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	12,417	$0.00	$0.00
Exercise	Common Stock	12,417	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 0 contracts (Direct); Common Stock — 110,623 shares (Direct)

Footnotes (1)

1. F1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

Key Figures

RSUs exercised: 12,417 units Common shares acquired: 12,417 shares Shares held after transaction: 110,623 shares +1 more

4 metrics

RSUs exercised 12,417 units Restricted stock units settled into common stock on May 19, 2026

Common shares acquired 12,417 shares Shares received from RSU settlement on May 19, 2026

Shares held after transaction 110,623 shares Director’s direct common stock holdings following the RSU settlement

RSU grant date May 22, 2025 Grant date for the 12,417 restricted stock units

Key Terms

Restricted Stock Units, derivative security, scheduled vesting date, annual meeting of stockholders

4 terms

Restricted Stock Units financial

"Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

scheduled vesting date financial

"This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date."

annual meeting of stockholders financial

"the day immediately preceding the Company's 2026 annual meeting of stockholders"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did ClearPoint Neuro (CLPT) director Pascal Girin report?

Pascal Girin reported settling restricted stock units into shares. On May 19, 2026, he exercised 12,417 restricted stock units, receiving 12,417 shares of ClearPoint Neuro common stock as part of a scheduled vesting event, rather than an open-market purchase or sale.

How many ClearPoint Neuro (CLPT) shares did Pascal Girin acquire in this Form 4?

Pascal Girin acquired 12,417 common shares through RSU settlement. These shares came from the exercise of 12,417 restricted stock units that vested according to their grant terms, with no cash exercise price reported for the conversion.

What are the vesting terms of Pascal Girin’s ClearPoint Neuro (CLPT) RSUs?

The RSUs were time-based and tied to the annual meeting schedule. Granted on May 22, 2025, the 12,417 restricted stock units vested on the earlier of the first anniversary of that grant date or the day immediately before ClearPoint Neuro’s 2026 annual stockholders’ meeting.

How many ClearPoint Neuro (CLPT) shares does Pascal Girin hold after this transaction?

After the RSU settlement, Pascal Girin holds 110,623 shares. The Form 4 shows his direct ownership of ClearPoint Neuro common stock increased by 12,417 shares, reflecting the full conversion of his vested restricted stock units into common stock.

Was Pascal Girin’s ClearPoint Neuro (CLPT) Form 4 a market sale or purchase?

The Form 4 reflects an RSU exercise, not a market trade. The transaction code "M" and zero exercise price indicate a derivative exercise and settlement of restricted stock units into common stock, rather than buying or selling shares on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/21/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Girin Pascal E R

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CALIFORNIA 92075

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/19/2026		M		12,417	A	(1)	110,623	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	05/19/2026		M			12,417	(1)	(1)	Common Stock	12,417	(1)	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. On May 22, 2025, the reporting person was granted 12,417 restricted stock units, vesting on the earlier of (i) the first anniversary of the grant date, or (ii) the day immediately preceding the Company's 2026 annual meeting of stockholders. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.

	/s/ Danilo D'Alessandro, by Power of Attorney for Pascal E. R. Girin	05/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)